Results 181 to 190 of about 92,115 (273)

Complete pathological response to neoadjuvant chemoradiotherapy in Crohn's disease-associated fistula adenocarcinoma: a case report. [PDF]

Front Med (Lausanne)
Dahmeni W, Souilem E, Hassen H, Ghdiri Y, Ahlem Z, Dahmoul A, Slama AB, Brahem A, Jaziri H, Mestiri S, Elleuch N, Hmissa S, Ksiaa M.   +12 more
europepmc   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

Identification of neoadjuvant chemoradiotherapy resistance-associated proteins in locally advanced rectal cancer: A pilot study. [PDF]

Oncol Lett
He JY, Dong Y, Chen C, Lu FH, Ran FW, Ding Q, Du Y, Liu TR, Zhang YY, Wang T, Chen YH, Zhao X, Xu SL, Li JJ.   +13 more
europepmc   +1 more source

Neoadjuvant PD‐1 Blockade Tislelizumab (BGB‐A317) in Combination With Etoposide and Platinum‐Based Chemotherapy for Limited‐Disease Small Cell Lung Cancer

MedComm, Volume 7, Issue 9, September 2026.
This study assessed neoadjuvant PD‐1 blockade plus chemotherapy in patients with resectable limited‐stage small cell lung cancer. Peri‐treatment biopsy and surgical samples were analyzed using bulk RNA sequencing and bioinformatics approaches.
Shiyue Wan, Shiqi Hu, Yilv Yan, Fenghuan Sun, Dongliang Bian, Jie Luo, Dong Xie, Wenxin He, Liang Duan, Yuming Zhu, Nan Song, Ming Liu, Hongcheng Liu, Gening Jiang, Peng Zhang   +14 more
wiley   +1 more source

Multivariable Radiomics Model for Predicting Programmed Death-Ligand 1 Expression After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma. [PDF]

Cancer Med
Do Jung H, Lee TH, Kim BH, Lee HS, Son J, Kim H, Kim HJ.   +6 more
europepmc   +1 more source

Long‐Term Prognosis and Immunotranscriptomic Landscape in Esophageal Squamous Cell Carcinoma With Different Pathological Responses to Neoadjuvant Chemoradiotherapy: A Retrospective Cohort Study

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This study comprehensively characterizes the long‐term prognosis and immunotranscriptomic landscape associated with different tumor regression grades (TRGs) in esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemoradiotherapy. By integrating bulk RNA‐seq, single‐cell transcriptomics, and multiplexed immunohistochemistry, we demonstrate ...
Jianye Yuan, Zelin Weng, Xinke Zhang, Fangqi Deng, Zihui Tan, Jian Zhong, Rui Chen, Xiuying Xie, Xiaodan Lin, Ting Lin, Yan Huang, Qianwen Liu, Jing Wen, Jianhua Fu   +13 more
wiley   +1 more source

Association between surgical timing and postoperative outcome in patients with residual esophageal cancer after neoadjuvant chemoradiotherapy. [PDF]

J Gastrointest Oncol
Kobayashi S, Tasaki K, Ogawa S, Li L, Matsuguma K, Murakami S, Kubo K, Hashimoto Y, Hamasaki K, Arai J, Kobayashi K, Matsumoto K, Eguchi S, Kanetaka K.   +13 more
europepmc   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

MedComm – Oncology, Volume 5, Issue 3, September 2026.
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley   +1 more source

Pathological Response of Locally Recurrent Rectal Cancer to Neoadjuvant Chemoradiotherapy. [PDF]

J Anus Rectum Colon
Yokoyama Y, Ozaki K, Nozawa H, Sasaki K, Murono K, Emoto S, Kaneko K, Matsuzaki H, Abe S, Nagai Y, Shinagawa T, Ishihara S.   +11 more
europepmc   +1 more source

Multi‐modal direct LINAC parameter prediction for pancreatic VMAT: An optimization‐free approach

Medical Physics, Volume 53, Issue 9, September 2026.
Abstract Background Pancreatic cancer Volumetric Modulated Arc Therapy (VMAT) planning presents a significant dosimetric challenge due to the high‐dose gradients required to spare adjacent, radiosensitive organs at risk (OARs) like the stomach and duodenum. This anatomical complexity has limited the scope of automated planning for this site.
Zixu Guan, Yukine Shimizu, Takahiro Iwai, Michio Yoshimura, Takashi Mizowaki, Mitsuhiro Nakamura   +5 more
wiley   +1 more source